恒瑞医药(01276.HK)：注射用甲苯磺酸瑞马唑仑上市许可申请获药监局受理|天天快报

Core Points - Jiangsu Hengrui Medicine Co., Ltd. has received the acceptance notice from the National Medical Products Administration for its drug application of injectable remimazolam tosylate [2] Group 1 - Drug Name: Injectable Remimazolam Tosylate [2] - Dosage Form: Injectable [2] - Acceptance Number: CXHS2500146 [2] - Application Stage: Market Approval [2] - Applicant: Jiangsu Hengrui Medicine Co., Ltd. [2] - Proposed Indication: Sedation during mechanical ventilation in intensive care [2]